We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?
Read MoreHide Full Article
Key Takeaways
CorMedix acquired Melinta for $300M, adding seven marketed therapies to its portfolio.
The deal boosts 2025 revenue outlook to $325-$350M, with EPS accretion expected in 2026.
Rezzayo offers near-term growth and is in phase III testing for expanded fungal infection use.
CorMedix (CRMD - Free Report) has taken a major step toward diversifying its revenue base and reducing reliance on a single product with the recent $300 million acquisition of Melinta Therapeutics. The move significantly expands the company’s marketed portfolio and strengthens its positioning in the hospital acute care and infectious disease markets.
Until now, CorMedix’s fortunes were tied almost entirely to its lead product, DefenCath (Taurolidine + Heparin). Approved by the FDA in late 2023, DefenCath is the first and only antimicrobial catheter lock solution available in the United States. It is indicated for reducing catheter-related bloodstream infections (CRBSIs) in adult patients with kidney failure undergoing chronic hemodialysis through a central venous catheter. While the approval marked a key milestone, the absence of a broader development pipeline left CorMedix exposed, with revenues dependent solely on DefenCath’s performance.
The acquisition of Melinta addresses this risk head-on by adding seven approved therapies — Minocin, Rezzayo, Vabomere, Orbactiv, Baxdela, Kimyrsa, and Toprol-XL — to CorMedix’s commercial portfolio.
The expanded portfolio not only strengthens the company’s revenue base but also positions it for near-term growth opportunities, particularly with Rezzayo, which is currently approved for the treatment of candidemia and invasive candidiasis in adults. The drug is also being evaluated in a phase III study for prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplant, with study completion expected in the first half of 2026. Positive data could support a regulatory filing for label expansion, further enhancing Rezzayo’s commercial potential.
Financially, CorMedix expects its 2025 pro forma revenues to be in the $325-$350 million range, reflecting the immediate contribution from Melinta’s portfolio, which generated $120 million in 2024. In 2025, CorMedix anticipates Melinta’s portfolio to generate $125 million to $135 million in revenues. The company expects the acquisition to be accretive to earnings per share beginning in 2026, supported by projected annual cost synergies of $35-$45 million.
Other Companies That Market Heparin
DefenCath combines taurolidine, an antimicrobial agent, with the anticoagulant heparin in a fixed-dose formulation designed for a niche population of kidney failure patients. CorMedix’s decision to acquire Melinta and add seven new products to its portfolio was also driven by the looming risk of potential new entrants in the CRBSI treatment market.
While CorMedix currently enjoys a first-mover advantage in the United States with no direct competitors in CRBSI prevention, the competitive landscape carries risks. Larger players, such as Pfizer (PFE - Free Report) , Amphastar Pharmaceuticals (AMPH - Free Report) , B. Braun, Baxter and Fresenius Kabi USA LLC, already market heparin across a range of indications in the United States. With their deeper pipelines, manufacturing scale and financial resources, these companies could quickly emerge as formidable rivals if they choose to pursue CRBSI-specific applications, potentially eroding CorMedix’s market exclusivity and long-term growth prospects.
Pfizer already markets Heparin Sodium Injection, an anticoagulant with broad clinical applications ranging from the treatment of venous thrombosis and pulmonary embolism to use in surgery, dialysis, and transfusion settings. Backed by its global scale, extensive clinical infrastructure and financial resources, Pfizer could quickly pivot to CRBSI-specific indications, posing a significant challenge to CorMedix’s foothold.
Amphastar Pharmaceuticals currently markets Enoxaparin, a complex low molecular weight heparin with multiple indications. AMPH controls its entire supply chain by producing the active pharmaceutical ingredient in-house, giving it stronger cost efficiencies and quality oversight. This vertically integrated model, combined with Amphastar Pharmaceuticals’ manufacturing expertise, underscores the competitive risk for CorMedix if the company decides to extend its anticoagulant capabilities into the CRBSI market targeted by DefenCath.
CRMD’s Stock Price, Valuation and Estimates
Shares of CorMedix have surged 37.2% so far this year compared with the industry’s 3% growth. The stock has also outperformed the sector and the S&P 500 index during the same time frame, as seen in the chart below.
CRMD Stock Price Movement
Image Source: Zacks Investment Research
From a valuation standpoint, CorMedix stock is expensive. Going by the price/book ratio, the company’s shares currently trade at 3.42 trailing 12-month book value per share, higher than 3.14 for the industry. The stock, however, is trading below its five-year mean of 3.55.
CRMD Stock Valuation
Image Source: Zacks Investment Research
Estimates for CorMedix’s 2025 earnings have improved from $1.10 to $1.52 per share in the past 60 days, and estimates for 2026 earnings have improved from $1.46 to $2.12 over the same timeframe.
Image: Bigstock
Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?
Key Takeaways
CorMedix (CRMD - Free Report) has taken a major step toward diversifying its revenue base and reducing reliance on a single product with the recent $300 million acquisition of Melinta Therapeutics. The move significantly expands the company’s marketed portfolio and strengthens its positioning in the hospital acute care and infectious disease markets.
Until now, CorMedix’s fortunes were tied almost entirely to its lead product, DefenCath (Taurolidine + Heparin). Approved by the FDA in late 2023, DefenCath is the first and only antimicrobial catheter lock solution available in the United States. It is indicated for reducing catheter-related bloodstream infections (CRBSIs) in adult patients with kidney failure undergoing chronic hemodialysis through a central venous catheter. While the approval marked a key milestone, the absence of a broader development pipeline left CorMedix exposed, with revenues dependent solely on DefenCath’s performance.
The acquisition of Melinta addresses this risk head-on by adding seven approved therapies — Minocin, Rezzayo, Vabomere, Orbactiv, Baxdela, Kimyrsa, and Toprol-XL — to CorMedix’s commercial portfolio.
The expanded portfolio not only strengthens the company’s revenue base but also positions it for near-term growth opportunities, particularly with Rezzayo, which is currently approved for the treatment of candidemia and invasive candidiasis in adults. The drug is also being evaluated in a phase III study for prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplant, with study completion expected in the first half of 2026. Positive data could support a regulatory filing for label expansion, further enhancing Rezzayo’s commercial potential.
Financially, CorMedix expects its 2025 pro forma revenues to be in the $325-$350 million range, reflecting the immediate contribution from Melinta’s portfolio, which generated $120 million in 2024. In 2025, CorMedix anticipates Melinta’s portfolio to generate $125 million to $135 million in revenues. The company expects the acquisition to be accretive to earnings per share beginning in 2026, supported by projected annual cost synergies of $35-$45 million.
Other Companies That Market Heparin
DefenCath combines taurolidine, an antimicrobial agent, with the anticoagulant heparin in a fixed-dose formulation designed for a niche population of kidney failure patients. CorMedix’s decision to acquire Melinta and add seven new products to its portfolio was also driven by the looming risk of potential new entrants in the CRBSI treatment market.
While CorMedix currently enjoys a first-mover advantage in the United States with no direct competitors in CRBSI prevention, the competitive landscape carries risks. Larger players, such as Pfizer (PFE - Free Report) , Amphastar Pharmaceuticals (AMPH - Free Report) , B. Braun, Baxter and Fresenius Kabi USA LLC, already market heparin across a range of indications in the United States. With their deeper pipelines, manufacturing scale and financial resources, these companies could quickly emerge as formidable rivals if they choose to pursue CRBSI-specific applications, potentially eroding CorMedix’s market exclusivity and long-term growth prospects.
Pfizer already markets Heparin Sodium Injection, an anticoagulant with broad clinical applications ranging from the treatment of venous thrombosis and pulmonary embolism to use in surgery, dialysis, and transfusion settings. Backed by its global scale, extensive clinical infrastructure and financial resources, Pfizer could quickly pivot to CRBSI-specific indications, posing a significant challenge to CorMedix’s foothold.
Amphastar Pharmaceuticals currently markets Enoxaparin, a complex low molecular weight heparin with multiple indications. AMPH controls its entire supply chain by producing the active pharmaceutical ingredient in-house, giving it stronger cost efficiencies and quality oversight. This vertically integrated model, combined with Amphastar Pharmaceuticals’ manufacturing expertise, underscores the competitive risk for CorMedix if the company decides to extend its anticoagulant capabilities into the CRBSI market targeted by DefenCath.
CRMD’s Stock Price, Valuation and Estimates
Shares of CorMedix have surged 37.2% so far this year compared with the industry’s 3% growth. The stock has also outperformed the sector and the S&P 500 index during the same time frame, as seen in the chart below.
CRMD Stock Price Movement
From a valuation standpoint, CorMedix stock is expensive. Going by the price/book ratio, the company’s shares currently trade at 3.42 trailing 12-month book value per share, higher than 3.14 for the industry. The stock, however, is trading below its five-year mean of 3.55.
CRMD Stock Valuation
Estimates for CorMedix’s 2025 earnings have improved from $1.10 to $1.52 per share in the past 60 days, and estimates for 2026 earnings have improved from $1.46 to $2.12 over the same timeframe.
CRMD Estimate Movement
CorMedix currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.